We are happy to announce that our company transitioned from a privately held limited company to a public limited company (SA). This transition marks an important milestone in our journey as a company, and we are thrilled to be taking this step forward.

This will allow us to broaden our investor base and access new sources of capital, which will help us to continue to grow and expand our business. It will also provide greater transparency and accountability to our shareholders and stakeholders.

Our mission remains unchanged: to develop new technologies for the treatment of unmet clinical needs.